ClinicalTrials.gg
CompletedNCT05913284Updated Oct 23, 2026

Intravenous Methadone in Perioperative Acute and Chronic Management in Chinese Adult Cardiac Surgical Patients

A Phase 3 interventional study of Methadone and Morphine in Pain, Postoperative, Pain, Acute and Pain, Chronic, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Chinese University of Hong Kong · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry.
  • Registered 4 months after the study started (first participant enrolled Jan 2023, registered May 2023).
Updated Oct 23, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies testing methadone in Pain, Postoperative — 8 open to participants now, 8 under way, 3 of them phase 3. Methadone · Pain, Postoperative.

Enrollment
15th of 37
86 · median 75
Started
2023
with 2 others
Phase 3
7 of 37
3 open now
Registered
27th of 37
by date
Lead sponsor
2 of 37
Chinese University of Hong Kong

Among the 37 studies testing methadone in Pain, Postoperative, this one is the 15th largest by enrollment, is one of 3 that started in 2023, is one of 7 in phase 3, and was the 27th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 37 studies testing methadone in Pain, Postoperative are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methadone

Methadone: first FDA approval 1947 (DOLOPHINE HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing methadone in Pain, Postoperative, or all of them as a file.
02

Study summary

Despite modern day improvements in pain treatment and availability of different analgesic modalities, suboptimal postoperative pain control remains an issue in cardiac surgical patients. Poorly controlled acute postoperative pain is associated with adverse physiological outcomes that impair the recovery of cardiac surgical patients. It is associated with decreased patient satisfaction, delayed postoperative ambulation, and the development of chronic postsurgical pain (CPSP).

Intravenous opioids such as fentanyl and morphine have been the mainstay of perioperative analgesia for cardiac surgery, either by intermittent boluses by healthcare staff or through a patient-controlled device (PCA). The primary problem with this mechanism of delivery is that significant fluctuations in serum opioid concentrations can occur, resulting in effects which range from inadequate analgesia to overdose and respiratory depression. In contrast to intermittent administration of short-acting opioids such as morphine and fentanyl, a single dose administration of methadone can be considered.

Read the detailed description

Despite modern day improvements in pain treatment and availability of different analgesic modalities, suboptimal postoperative pain control remains an issue in cardiac surgical patients. Acute postoperative pain is common among cardiac surgical patients, particularly within the first 2 days after surgery, with reported at least moderate intensity. There could be many facets for postoperative pain after adult cardiac surgery. Pain can be caused by surgical incisions and dissections, sternal fracture or incomplete bone healing, multiple drainage cannulas and chest tubes and sternal wound infections. Poorly controlled acute postoperative pain is associated with adverse physiological outcomes that impair the recovery of cardiac surgical patients. It is associated with decreased patient satisfaction, delayed postoperative ambulation, and the development of chronic postsurgical pain (CPSP). The association between sternotomy pain and pulmonary complications has been observed, and the sympathetic activation secondary to pain can induce myocardial ischemia and arrhythmias. Pain control has also been pointed out as one of the major concerns to cardiac surgical patients in intensive care unit. Therefore, optimal acute pain control not only can improve clinical outcomes, but also improves patient satisfaction after cardiac surgery.

Postoperative pain that persists beyond the normal time for tissue healing is increasingly recognized as an important complication after various types of surgery. According to the International Association for Study of Pain, CPSP is defined as the persistence of pain at surgical site or referred area, at least 3 months following the surgical procedure. CPSP is common after cardiac surgery. The reported incidence was 28% to 56% up to 2 years postoperatively. Several mechanisms have been involved in the development of chronic pain after sternotomy. These include dissection, nerve entrapment by sternal wires, sternal retraction, ribs fractures, and intercostal neuralgia as a consequence of nerve damage during dissection of the internal mammary artery during coronary artery bypass graft (CABG). In addition, poorly controlled pain has been a general risk factor for the development of CPSP. All can stimulate the release of pro-inflammatory cytokines which sensitize the afferent nociceptive fibres to cause chronic pain. CPSP has the potential to impact daily functioning and quality of life of patients, as well as increasing the healthcare costs. CARDpain study reported that among those with CPSP, over 50% had significant pain-related interferences with activities of daily living (family and home responsibilities, recreation and employment) at 3, 6 and 12 months following cardiac surgery. Therefore, apart from optimal acute pain control, it is equally important to prevent and manage CPSP, to ensure better satisfaction and quality of lives for our patients.

Intravenous opioids such as fentanyl and morphine have been the mainstay of perioperative analgesia for cardiac surgery, either by intermittent boluses by healthcare staff or through a patient-controlled device (PCA). The primary problem with this mechanism of delivery is that significant fluctuations in serum opioid concentrations can occur, resulting in effects which range from inadequate analgesia to overdose and respiratory depression. These peaks and troughs of analgesia that occur with intermittent opioids administration may explain the suboptimal pain control during the initial postoperative period. In contrast to intermittent administration of short-acting opioids such as morphine and fentanyl, a single dose administration of methadone can be considered. Methadone was conventionally used in cancer and chronic pain management. It can be administered via oral, intravenous, and other parenteral routes. Despite being an often-used alternative to morphine, it remains relatively invisible in perioperative settings. Methadone is a unique opioid that may provide several important potential benefits for surgical patients in the perioperative period. It is a potent mu receptor agonist with a rapid onset and longest half-life (24-36 hours) of the clinically used opioids. According to a pharmacokinetic study, central nervous system effect site methadone concentration rapidly equilibrates with plasma concentrations, evidenced by a short lag time between plasma concentrations and effects (t1/2ke0 4min). This is comparable to the rapid onset and effect compartment equilibration of fentanyl and sulfentanil (5-6min), and in contrast the slow onset time of morphine, where t1/2ke0 has been reported to exceed 4 hours. In addition, as reviewed in an editorial, when methadone is administered at a dose of 20mg or higher, the duration of analgesia approximates the half-life of 24-36 hours. Therefore, a single intravenous dose 20mg administered to an adult at induction of anaesthesia should provide a rapid onset and significant pain relief up to 1-2 days postoperatively, which is the period reported to have the highest pain score after cardiac surgery. Methadone is also a N-methyl-D-aspartate (NMDA) receptor antagonist. It has been reported to possess anti-hyperanalgesic and anti-allodynic properties, that is important in preventing pain sensitization and the development of CPSP, which is of high risk in cardiac surgical patients.

There have been few randomized controlled trials comparing between intravenous methadone and other opioids for perioperative pain control in cardiac surgery requiring sternotomy, and none in the Asian populations. In addition, the effect of methadone on chronic postsurgical pain in cardiac surgical patients has not been widely reported in literature. Therefore, the primary aim of this pilot randomized controlled trial is a feasibility study to evaluate the protocol and the effect of methadone on acute and chronic pain control after open cardiac surgery, compared with conventional approach of opioid-based analgesia using morphine and fentanyl. In addition, the effects of methadone on opioids consumption, opioid-related side effects, patient satisfaction, postoperative extubation times, and length of stay in hospital and ICU will be determined. The investigators hypothesized that intravenous methadone is associated with a reduction in opioids requirement intraoperatively and in the first 24 hours after surgery, and improvement in acute pain score at 12h after extubation. The secondary hypothesis is that patients administered with methadone would experience less CPSP compared with standard treatment group.

The investigators hypothesized that intravenous methadone is feasible and applicable in cardiac anaesthesia, and is associated with opioid-sparing intraoperatively and within 24h after surgery, as well as better acute and chronic pain control when compared to conventional opioid-based approach with morphine and fentanyl in adult cardiac surgical patients. The aims of the study are as follows:

  1. To determine the feasibility of using intravenous methadone in adult cardiac surgical patients
  2. To evaluate the effect of methadone in acute and chronic pain management in adult cardiac surgical patients requiring sternotomy
03

Conditions studied

  • Pain, Postoperative
  • Pain, Acute
  • Pain, Chronic
  • Anesthesia

Keywords

  • cardiac surgery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 or older
  • Elective primary isolated coronary artery bypass grafting, aortic valve repair/replacement, mitral valve repair/replacement or combined coronary artery bypass/valve procedure via sternotomy
  • Expected extubation within 12 hours of surgery

Exclusion criteria

Exclusion Criteria:

  • emergency surgery
  • aortic surgery
  • redo surgery
  • preoperative renal failure requiring renal replacement therapy or \<30ml/min (calculated by Cockcroft-Gault Formula
  • liver dysfunction (liver enzymes twice upper limit normal)
  • \< 40% at baseline
  • mechanical circulatory support in perioperative period
  • history of chronic pain or who regularly used pain medications (except paracetamol and non-steroidal anti-inflammatory drugs)
  • history of psychiatric illnesses or illicit drug use
  • intraoperative use of remifentanil
  • unable to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Methadone group

    Upon induction of anaesthesia, intravenous methadone 0.2mg/kg (maximum dose 20mg) in blind labelling will be administered by infusion over 30 minutes. No further morphine will be given throughout the operation, but administration of Intraoperative fentanyl will be left to the discretion of the attending anaesthesiologists

    Drug: Methadone

  • Active comparator
    Morphine group

    Upon induction of anaesthesia, intravenous morphine that is of equipotent dose as 0.2mg/kg methadone or 20mg methadone if maximum dose of interventional drug is reached) in blind labelling will be administered by infusion over 30 minutes. No further morphine will be given throughout the operation, but administration of Intraoperative fentanyl will be left to the discretion of the attending anaesthesiologists

    Drug: Morphine

Interventions

  • The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes

  • The drug will be prepared by study investigator and then handover to the anaesthesiologist which is blinded to the study. The syringe will be labelled as study drug and given on induction of anaesthesia as intravenous infusion over 30 minutes

06

What researchers measure

Primary outcomes

  1. Proportion of patients that can be recruited

    defined as the number of patients that fit the recruitment criteria divided by the total number of elective cardiac surgical patients over a period of time

    Time frame: At recruitment

  2. Proportion of patients excluded based on inclusion and exclusion criteria

    Number of patients excluded divided by the total number of elective cardiac surgical patients over a period of time

    Time frame: At recruitment

  3. Cardiac arrhythmia from side effects of methadone

    New-onset cardiac arrhythmia or prolonged QTc attributed to methadone

    Time frame: intraoperatively

  4. Cardiac arrhythmia from side effects of methadone

    New-onset cardiac arrhythmia or prolonged QTc attributed to methadone

    Time frame: Within 72 hours postoperatively

Secondary outcomes

  1. Ventilator time

    The time at which the patient is successfully weaned to spontaneous breathing according to ICU ASV protocol

    Time frame: Within 24 postoperatively in ICU

  2. Total morphine consumption

    Morphine consumption within 24 hours after operation

    Time frame: intraop and postop within 24 hours

  3. Intraoperative fentanyl consumption

    Fentanyl consumption intraoperatively

    Time frame: intraoperative

  4. Pain score at rest

    Measured using numerical rating scale. It ranges from 0-10. The higher the score, the worse the pain

    Time frame: Within 72 hours postop

  5. Pain score on exertion

    Measured using numerical rating scale

    Time frame: within 72 hours postop

  6. Time to first morphine rescue

    This is the time the patient feels the need to use morphine from patient-controlled analgesia machine

    Time frame: Postoperatively up to 24 hours

  7. Nausea and vomiting

    Number of episodes of postoperative nausea and vomiting

    Time frame: Postoperative within 72 hours

  8. Length of hospital stay

    Number of hours the patient has to stay in hospital

    Time frame: upon discharge from hospital (assessed up to day 10)

  9. Length of ICU stay

    Number of hours the patient has to stay in ICU

    Time frame: Upon discharge from ICU (assessed up to day 2)

  10. BPI at 3 months

    Measured using Brief Pain Inventory which consists of pain measurement that affects daily living from scale 0-10. The higher the score, the worse the pain

    Time frame: At 3 months postop

  11. BPI at 6 months

    Measured using Brief Pain Inventory which consists of pain measurement that affects daily living from scale 0-10. The higher the score, the worse the pain

    Time frame: At 6 months postop

  12. NPQ at 3 months

    Measured using Neuropathic Pain Questionnaire that has scale 0-100. The higher the score, the worse the pain

    Time frame: At 3 months postop

  13. NPQ at 6 months

    Measured using Neuropathic Pain Questionnaire that has scale 0-100. The higher the score, the worse the pain

    Time frame: At 6 months postop

  14. PCS at 3 months

    Measured using Pain Catastrophizing Scale. It consists of 13 items with each item scaled 0-4. The higher the score, the worse the pain

    Time frame: At 3 months postop

  15. PCS at 6 months

    Measured using Pain Catastrophizing Scale. It consists of 13 items with each item scaled 0-4. The higher the score, the worse the pain

    Time frame: At 6 months postop

07

Study locations

1 site
  • Prince of Wales Hospital
    Hong Kong, Hong Kong
08

References and documents

Publications

  • Wong HMK, Wong WT, Liu X, Au SSW, Wong RHL. Intravenous methadone for perioperative acute and chronic pain management in Chinese adult cardiac surgical patients: A protocol for pilot randomized controlled trial. PLoS One. 2025 Jun 2;20(6):e0323820. doi: 10.1371/journal.pone.0323820. eCollection 2025. PubMed 40455731 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Dec 2024, 22 months.

Of 124 non-industry phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 22 months is close to that.

Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: start Jan 2024 → Jan 2023, primary completion Feb 2026 → Dec 2024 and completion Apr 2026 → Dec 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2023
First posted
Jun 22, 2023
StartActual
Jan 15, 2023was Jan 2024
Primary completionActual
Dec 1, 2024was Feb 2026
CompletionActual
Dec 10, 2024was Apr 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 23, 2026
Start date
Jan 15, 2024→Jan 15, 2023
Oct 23, 2026
Primary completion
Feb 1, 2026→Dec 1, 2024 (actual)
Oct 23, 2026
Study completion
Apr 1, 2026→Dec 10, 2024 (actual)
Oct 23, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 40455731 ↗
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Active, not recruiting→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 40455731 ↗
    Start date Jan 15, 2024→Jan 15, 2023
    Primary completion Feb 1, 2026→Dec 1, 2024 (now actual)
    Study completion Apr 1, 2026→Dec 10, 2024 (now actual)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05913284
Responsible party
WONG MAN KIN (Principal Investigator, Chinese University of Hong Kong) — Principal investigator
First posted
Jun 22, 2023
Start date
Jan 15, 2023
Primary completion
Dec 1, 2024
Completion
Dec 10, 2024
Last update
Oct 23, 2026

Study contacts

Man Kin WONG, MBChB
principal investigator · Chinese Unversity of Hong Kong

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methadone

Start the discussion